Meeting
2018 Gastrointestinal Cancers Symposium
A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer.
Authors
Vaibhav Sahai
University of Michigan, Ann Arbor, MI
Vaibhav Sahai , Kent A. Griffith , Mark Zalupski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT03101566
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr TPS541)
DOI
10.1200/JCO.2018.36.4_suppl.TPS541
Abstract #
TPS541
Poster Bd #
Q17
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A multi-center randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first line therapy for patients with advanced unresectable biliary tract cancer.
First Author: Vaibhav Sahai
Poster
2020 ASCO Virtual Scientific Program
A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01).
First Author: Vaibhav Sahai
Poster
2021 ASCO Annual Meeting
A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04).
First Author: Vaibhav Sahai
Poster
2023 ASCO Annual Meeting
Sintilimab plus gemcitabine and cisplatin as a first-line treatment for patients with advanced biliary tract cancer: A biomolecular exploratory, phase II clinical trial.
First Author: Zhen-gang Yuan